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Abstract
Heart-specific  CD4+ T cells have been implicated in development and progression of myocarditis in mice and in humans. 
Here, using mouse models of experimental autoimmune myocarditis (EAM) we investigated the role of heart non-specific 
 CD4+ T cells in the progression of the disease. Heart non-specific  CD4+ T cells were obtained from DO11.10 mice expressing 
transgenic T cell receptor recognizing chicken ovalbumin. We found that heart infiltrating  CD4+ T cells expressed exclu-
sively effector (Teff) phenotype in the EAM model and in hearts of patients with lymphocytic myocarditis. Adoptive transfer 
experiments showed that while heart-specific Teff infiltrated the heart shortly after injection, heart non-specific Teff effectively 
accumulated during myocarditis and became the major heart-infiltrating  CD4+ T cell subset at later stage. Restimulation 
of co-cultured heart-specific and heart non-specific  CD4+ T cells with alpha-myosin heavy chain antigen showed mainly 
Th1/Th17 response for heart-specific Teff and up-regulation of a distinct set of extracellular signalling molecules in heart 
non-specific Teff. Adoptive transfer of heart non-specific Teff in mice with myocarditis did not affect inflammation severity at 
the peak of disease, but protected the heart from adverse post-inflammatory fibrotic remodelling and cardiac dysfunction at 
later stages of disease. Furthermore, mouse and human Teff stimulated in vitro with common gamma cytokines suppressed 
expression of profibrotic genes, reduced amount of α-smooth muscle actin filaments and decreased contraction of cardiac 
fibroblasts. In this study, we provided a proof-of-concept that heart non-specific Teff cells could effectively contribute to 
myocarditis and protect the heart from the dilated cardiomyopathy outcome.
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Abbreviations
EAM  Experimental autoimmune myocarditis
DCM  Dilated cardiomyopathy
α-MyHC  Alpha-myosin heavy chain
CFA  Complete Freud’s adjuvant
Tn/Teff  Naïve/effector  CD4+ T cell
TCR  T cell receptor
APC  Antigen presenting cell
γc-cytokines  Common gamma cytokines
IL  Interleukin
αSMA  α-Smooth-muscle actin
LN  Lymph node
OVA  Ovalbumin
Th  CD4+ T helper cell
Introduction
Myocarditis most commonly results from cardiotropic infec-
tions or tissue damage, followed by the activation of heart-
specific autoimmunity [3, 34]. Lymphocytic myocarditis, 
characterized by extensive infiltration of lymphocytes and 
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monocytes with signs of cardiomyocyte necrosis, represents 
the most common type of the disease [9]. Clinical presenta-
tion of the disease ranges from acute or chronic to fulminant 
myocarditis [35]. In about one-third of biopsy-proven cases, 
myocarditis progresses to dilated cardiomyopathy (DCM), 
characterized by extensive fibrosis, ventricular dilation and 
heart failure [9, 14]. The mechanisms underlying variable 
clinical outcomes of myocarditis remain, however, poorly 
understood.
Mouse models of experimental autoimmune myocarditis 
(EAM) reflect key aspects of the human disease [34]. In 
the classical EAM model, immunization with alpha-myosin 
heavy chain (α-MyHC) peptide and complete Freund’s adju-
vant (CFA) induces myocarditis in susceptible mice. On fol-
low-up, inflammation in the myocardium resolves and some 
mice develop progressive cardiac fibrosis, ventricular dila-
tion and heart failure [4, 5, 21]. In the α-MyHC/CFA model, 
autoreactive  CD4+ T cells play a central role in disease 
induction. Mechanistically, circulating α-MyHC-reactive 
 CD4+ T cells, which escape the negative selection in the 
thymus [27] set the biological basis for EAM development. 
Following α-MyHC/CFA immunization, antigen-present-
ing cells (APCs) activate α-MyHC-reactive  CD4+ T cells. 
During the initial phase, naïve  CD4+ T (Tn) cells become 
activated with antigen in the lymphatic system, where they 
undergo phenotypic changes. Tn cells convert into the effec-
tor (Teff) phenotype, expand and acquire new migratory 
properties [16]. In the effector phase, α-MyHC-reactive 
 Teff migrate into cardiac tissue, where they re-encounter 
α-MyHC antigen. This antigen-dependent response in the 
heart triggers production of proinflammatory cytokines, 
which induce myocarditis. Accordingly, adoptive transfer 
of  CD4+ T cells isolated from α-MyHC/CFA immunized 
mice can convey disease from the host to recipient [30, 36]
The adverse post-inflammatory remodeling, including 
an excessive fibrotic response, characterizes progression of 
myocarditis to DCM and end-stage heart failure [6, 19]. In 
fact, accumulation of cardiac fibroblasts and their transfor-
mation into myofibroblasts is the hallmark of cardiac fibrosis 
[24].  CD4+ T cells and particularly the Th17 subset have 
been implicated in transition from myocarditis to DCM 
phenotype [2, 29]. Insight from other models also points 
to autoreactive  CD4+ T cells as key mediators of cardiac 
fibrosis [15, 26].
In contrast to well-defined antigen-dependent responses, 
our understanding of antigen-independent mechanisms 
of  CD4+ T cells is limited. It has been demonstrated that 
such antigen-independent stimulation of  Teff, called also a 
bystander activation, could effectively contribute to  CD4+ 
T cell expansion and function in a specific inflammatory 
condition [10]. Innate stimuli [18, 32] and cytokines of the 
common gamma family (γc-cytokines IL-2, IL-7, IL-15 
and IL-21) [33] have been recognized as mediators of the 
bystander activation of  CD4+ T cells. So far, however, the 
role of antigen-independent mechanisms and heart non-spe-
cific  CD4+ T cells in myocarditis remained elusive.
Methods
EAM induction and adoptive T cell transfer
EAM was induced in 6–8 weeks old BALB/c or CD45.1-tg 
mice using an established protocol (see Supplemental Meth-
ods). In respective experiments, EAM mice were injected 
intravenously with either DO11.10+ Teff, DO11.10+ Tn or 
TCR-M Teff (3–5 × 106 per mouse) on days 17 and 20. For 
adoptive transfer, 6–8 weeks old BALB/c mice were sub-
lethally irradiated (5.5 Gy) using a Gammatron (Co-60) and 
intravenously injected with 3–5 × 106 CD45.1+ Teff, TCR-M 
Teff and/or DO11.10+ Teff per mouse. Sublethal irradiation 
depletes host’s T cells and thereby enables efficient engraft-
ment and propagation of adoptively transferred T cells. Mice 
were euthanised by exposure to > 70% carbon dioxide or 
anesthetic overdose. All animal experiments were approved 
by local authorities and performed in accordance with Swiss 
federal and Polish law and the Guide for the Care and Use of 
Laboratory Animals, published by the US National Institutes 
of Health (NIH Publication, 8th Edition, 2011).
Generation of Teff
Erythrocyte-lysed splenocytes/iLN cells were isolated 
from α-MyHC/CFA immunized CD45.1-tg mice at day 
17 (CD45.1+ Teff), untreated TCR-M-tg (TCR-M Teff) or 
untreated DO11.10-tg (DO11.10+ Teff) mice. Teff were gen-
erated by ex vivo  CD4+ T cell activation with the respective 
antigen in the presence of APCs for 72 h (see Supplemental 
Methods). Activated  CD4+ T cells purified by MACSorting 
using mouse anti-CD4 magnetic beads (Miltenyi) were used 
as Teff for adoptive transfer experiments. For in vitro use, 
Teff isolated from spleens/LN and hearts were additionally 
purified by FACSorting for  CD4+CD44hiCD62Llow cells. Tn 
were isolated from spleens of DO11.10-tg mice and puri-
fied using CD4 positive MACSorting and FACSorting for 
 CD4+CD44lowCD62Lhi cells using FACS Aria III.
Human  CD4+ T cell subsets were sorted from periph-
eral blood mononuclear cells (PBMCs) isolated from 
peripheral blood buffy coats of healthy donors (Blutspende 
Zurich, Switzerland), obtained with informed consent 
in accordance with the Declaration of Helsinki. PBMCs 
were isolated using Lympholyte (Cederlane) density gra-
dient separation according to manufacturer’s instruc-
tions.  CD4+ T cells were enriched by MACSorting using 
human anti-CD4 magnetic beads (Miltenyi).  CD4+ T cell 
subpopulations were further sorted using FACS Aria III 
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(BD Bioscience) based on the respective surface marker 
phenotypes:  CD45RA+CD45RO−CCR7+CD27+ (Tn) and 
 CD45RA−CD45RO+CCR7−CD27− (Teff).
CD4+ T cell proliferation
CD4+ T cells were isolated from mouse erythrocyte-lysed 
splenocytes/LNs or human PBMCs by MACS or sorted from 
hearts digested with Liberase (Roche).  CD4+ T cell sub-
populations were isolated using FACS Aria III. Cells were 
labeled with 2.5 μM CFSE or 5 μM CellTrace Violet Cell 
Proliferation Kit (both Life Technologies) and either injected 
into recipient mice or cultured in vitro in the respective con-
ditions (see Supplemental Methods). Cell proliferation was 
analyzed with LSRII Fortessa analyzer (BD Bioscience) and 
FlowJo software (Tree Star) using the Proliferation platform.
CD4+ T cell and cardiac fibroblast co‑culture
CD4+ T cell subpopulations were isolated from mouse or 
human  CD4+ T cell fractions with FACS Aria III cell sorter 
and cultured on confluent mouse or human cardiac fibro-
blasts, respectively (see Supplemental methods).
Flow cytometry and cell sorting
Single cell suspensions were prepared either from digested 
mouse hearts, erythrocyte-lysed splenocytes/LNs, or mouse 
and human PBMCs (see Supplemental methods). Freshly 
isolated or cultured cells were subjected to CD4 positive 
MACSorting and/or stained with the appropriate combina-
tion of fluorochrome-conjugated mouse/human antibod-
ies (see Supplemental methods). Cells were analyzed with 
LSRII Fortessa analyzer. In the respective experiments, T 
cell fractions were sorted with FACSAria III (purity > 98%). 
For intracellular protein staining, cardiac fibroblasts were 
stained with anti-mouse/human αSMA (Sigma) and anti-
human collagen I-biotin (Acris) antibodies (see Supplemen-
tal methods) and analyzed with LSRII Fortessa analyzer.
Histopathology, immunohistochemistry 
and immunocytochemistry
Conventional hematoxylin/eosin and Masson’s trichrome 
staining were used to assess cardiac inflammation and 
fibrosis, respectively (see Supplemental methods). Immu-
nopositive cells (for CD3, CD45, CD45.1, CD90.1) and 
fibrotic markers (Masson’s Trichrome; αSMA; periostin, 
vimentin, both Abcam) were quantified using Olympus 
BX51 microscope and cellSens (Olympus) or Fiji software. 
Formalin fixed, paraffin embedded human heart tissue from 
10 lymphocytic myocarditis patients were obtained from 
the Biobank of the Institute for Pathology and Neuropathol-
ogy, University Hospital Tubingen in accordance with local 
ethical regulations and stained using rabbit anti-human CD4 
(EPR6855, Abcam), mouse anti-human CD45RO (UCHL-
1, eBioscience) and mouse anti-human CD45RA (HI100, 
eBioscience); see Supplemental Methods. Image acquisi-
tion was performed with a Zeiss AxioObserver Z1 widefield 
microscope and processed by ImageJ.
Human and mouse cardiac fibroblasts were stained with 
anti-mouse/human αSMA antibody and phalloidin (Sigma); 
see Supplemental methods. Image acquisition was per-
formed with a Leica DM IRE2 microscope equipped with 
the Nomarski Interference Contrast and the Operetta high-
content screening platform (Perkin–Elmer).
Echocardiography
Transthoracic echocardiography was performed using a 
Vevo 2100 system equipped with 30-MHz transducer (Vis-
ualSonics). Anesthesia was induced by 5% isoflurane and 
confirmed by the absence of the withdrawal reflex of one 
of the hind paws. During echocardiogram acquisition iso-
fluorane was reduced to 1.5–2%. The heart was imaged in 
the bidimensional (2-D) mode, in the parasternal long-axis, 
short-axis and apical 4-chamber views. Detailed description 
is available in the Supplemental methods.
Statistics
Where relevant, data were analyzed by unpaired, two-tailed 
Student’s t test, one-way ANOVA followed by the Dun-
nett’s post hoc test (for normally distributed data), or by 
Mann–Whitney test (for nonparametric data). Differences 
were considered statistically significant for p < 0.05. All 
analyses were performed with GraphPad Prism 6 software 
and values are expressed as mean with SEM or SD.
For the extensive materials and methods we refer to the 
Supplemental methods.
Results
CD44hiCD62Llow cells represent the effector subset 
of  CD4+ T cells in EAM
To characterize the phenotype of inflammatory  CD4+ T 
cells in human myocarditis, we analyzed cardiac biopsies 
of 10 patients with acute lymphocytic, virus-negative myo-
carditis (Supp. Table 1). Biopsies were evaluated using 
histology and immunofluorescence staining for detection 
of CD4, CD45RA (expressed on resting/naïve T cells) and 
CD45RO (expressed on activated and memory T cells). As 
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shown by the representative staining (Supp. Fig. 1), nearly 
all  CD4+ cells stained positive for CD45RO and negative for 
CD45RA, indicating that heart infiltrating  CD4+ T cells in 
patients with acute lymphocytic myocarditis almost exclu-
sively express a phenotype of activated Teff. Next, we char-
acterized heart-specific  CD4+ T cells in the mouse model 
of EAM.  CD4+ T cells were isolated from blood and lym-
phoid organs of mice immunized with α-MyHC and CFA 
(Fig. 1a) 5–7 days after immunization (before myocarditis 
onset) and were further stimulated ex vivo for 3–5 days 
with α-MyHC antigen in the presence of APCs. Cells iso-
lated from inguinal lymph nodes (LNs) located at the site 
of α-MyHC antigen injection showed the most pronounced 
α-MyHC-specific proliferation, suggesting local activation 
of heart-reactive  CD4+ T cells (Supp. Fig. 2). To identify 
α-MyHC-responsive subsets, we sorted four populations of 
 CD4+ T cells, based on their surface expression of CD44 and 
CD62L markers (Fig. 1b). A robust proliferative response 
to α-MyHC was observed only for the  CD44hiCD62Llow Teff 
population (Fig. 1c, Supp. Fig. 3). During the early phase 
of myocarditis (EAM day 17), α-MyHC-reactive Teff were 
detectable not only in inguinal LNs, but also in mediastinal 
LNs, mesenteric LNs, blood, spleen and the heart (Fig. 1d). 
As expected, nearly all  CD4+ T cells infiltrating cardiac tis-
sue displayed the  CD44hiCD62Llow Teff phenotype. When 
isolated and exposed to α-MyHC antigen presented by 
APCs, these heart-infiltrating Teff extensively proliferated 
and produced inflammatory cytokines (Fig. 1d, e).
Heart non‑specific Teff effectively accumulate 
in the inflamed myocardium
Adoptive transfer of α-MyHC-re-stimulated  CD4+ T cells 
isolated from inguinal LNs and spleens of α-MyHC/CFA 
immunized wild-type donor mice expressing CD45.1+ 
alloantigen, effectively induced myocarditis in sub-lethally 
irradiated CD45.2+ wild-type recipients (Fig. 2a). More than 
80% of donor CD45.1+CD4+ cells displayed Teff phenotype 
and these cells effectively accumulated in the hearts of the 
recipients (Fig. 2b), confirming the potential of heart-reac-
tive Teff to trigger myocarditis.
We adopted this T cell transfer model to study mecha-
nisms of T cell trafficking to the heart. To address the dif-
ferential role of heart-specific and heart non-specific T cells, 
we used  CD4+ T cells from TCR-M and DO11.10 transgenic 
mouse strains, which expressed transgenic TCRs on their 
 CD4+ T cells. In TCR-M mice, T cells react exclusively 
to α-MyHC antigen and these mice develop spontaneous 
myocarditis [31]. On the other hand, chicken ovalbumin 
(OVA)-reactive DO11.10+  CD4+ T cells from DO11.10 
transgenic mice were used as a source of heart non-specific 
 CD4+ T cells. To obtain Teff for the adoptive transfer experi-
ments, splenic and iLN cells from the respective donors were 
activated with their respective cognate antigen for 72 h and 
 CD4+ T cells were sorted for experiments. Adoptive transfer 
of heart non-specific DO11.10+ Teff failed to trigger inflam-
mation (Fig. 2a), but DO11.10+  CD4+ T cells entered to 
a limited extent non-inflamed cardiac tissue (Fig. 2c). In 
contrast, heart-reactive TCR-M Teff (which express CD90.1 
alloantigen [31]) efficiently accumulated in the recipient 
hearts after adoptive transfer, although they induced myo-
carditis less efficiently than CD45.1+CD4+ T cells obtained 
from α-MyHC/CFA immunized mice (Fig. 2a).
Next, we co-transferred heart non-specific DO11.10+ 
Teff together with α-MyHC-re-stimulated CD45.1+ Teff 
from α-MyHC/CFA immunized mice. In inflamed hearts, 
we found not only myocarditis-inducing α-MyHC-reactive 
CD45.1+ Teff, but also a massive accumulation of heart 
non-specific DO11.10+ Teff (Fig. 2c). The total amount 
of DO11.10+ Teff was substantially higher in the inflamed 
hearts compared to the non-inflamed organs 10 days after 
adoptive transfer (Fig. 2d), demonstrating that the inflam-
matory response effectively attracted heart non-specific Teff 
into the heart.
To compare antigen-dependent and antigen-independ-
ent expansion of Teff in the inflamed myocardium, we co-
delivered α-MyHC-reactive CD45.1+ Teff from α-MyHC/
CFA immunized mice together with heart-specific TCR-M 
Teff and heart non-specific DO11.10+ Teff. Four days after 
adoptive transfer, we detected all three injected Teff in the 
recipient heart and TCR-M cells showed the most efficient 
heart-specific accumulation (Fig. 3a, b). However, at the 
peak of inflammation at day 10, DO11.10+  CD4+ T cells 
represented more than 50% of Teff in inflamed hearts, becom-
ing the dominant heart-infiltrating  CD4+ T cell population 
(Fig. 3b).
To better characterize antigen-dependent and antigen-
independent  CD4+ T cell responses, splenocytes of mice 
adoptively co-transferred with CD45.1+ Teff (obtained from 
α-MyHC/CFA immunized mice) and DO11.10+ Teff were 
isolated and cultured with or without α-MyHC peptide for 
24 h. Next, CD45.1+ Teff and DO11.10+ Teff were sorted and 
analyzed for the whole genome transcriptomics (Fig. 4a). 
The analysis showed differential response of CD45.1+ 
Teff and DO11.10+ Teff to α-MyHC stimulation (Fig. 4b). 
Antigen-dependent stimulation of CD45.1+ Teff resulted in 
response with Th cytokines (Il17a, Il17f, Ifng, Il5, Il22), 
chemokines (Ccl20, Cxcl10) and hematopoietic growth fac-
tors (Csf1, Csf2, Fig. 4c). In contrast, antigen-independent 
response of DO11.10+  Teff resulted in the up-regulation of 
inflammatory cytokines of TNF superfamily (Tnf, Lta), IL-6 
family (Osm, Lif) and others (Mif, Il4, Flt3l, Fig. 4c).
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Fig. 1  Teff phenotype of heart-reactive  CD4+ T cells in α-MyHC/
CFA-induced EAM. BALB/c mice received subcutaneous injection 
of α-MyHC/CFA into the right inguinal region as shown in panel a. 
 CD4+ T cells obtained from the right iLN 7 days after immunization 
were sorted into four fractions, labelled with CFSE and cultured for 
3  days on APCs with or without α-MyHC. Panel b shows the gat-
ing strategy for  CD4+ T cell subpopulations in viable  CD4+  CD45+ 
population isolated from iLN: Teff effector, Tcm central memory, Tn 
naïve and Tun undefined T cells. Percentage of proliferating CFSE-
labelled  CD4+ T cell subpopulations is quantified in panel c. Data are 
representative of three independent experiments, *p < 0.05 (unpaired 
Student’s t test). Panel d shows representative phenotype analyses of 
viable  CD4+CD45+ cells and frequencies of  CD4+CD44hiCD62Llow 
cells (Teff) in indicated organs at day 17 (active myocarditis). Teff from 
respective organs were sorted, labelled with CFSE and stimulated 
with α-MyHC peptide in presence of APCs for 5 days. Proliferation 
is shown as dilution of CFSE dye in viable  CD3+CD4+ population. 
Supernatant levels of indicated cytokines secreted by Teff isolated 
from the heart are presented in panel e. Data are representative of two 
independent experiments. iLN inguinal lymph node, mesLN mesen-
teric lymph node, medLN mediastinal lymph node, n.d. not detected
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Heart non‑specific Teff do not affect myocarditis 
severity, but protect from post‑inflammatory 
fibrosis and cardiac dysfunction
To address functional consequences of differential  CD4+ T 
cell responses, we analyzed heart sections of mice receiving 
α-MyHC-reactive CD45.1+ Teff (obtained from α-MyHC/
CFA immunized mice) with or without heart non-spe-
cific DO11.10+ Teff. Accumulation of heart non-specific 
DO11.10+ Teff neither affected myocarditis severity scores, 
nor the total number of  CD3+ and  CD45+ infiltrates in car-
diac sections (Fig. 5). Next, we addressed the impact of heart 
non-specific Teff on cardiac fibrosis in α-MyHC/CFA-immu-
nized BALB/c mice. Immunized mice received two doses of 
either antigen-activated DO11.10+ or TCR-M Teff, or non-
activated DO11.10+ Tn shortly before the onset of myocar-
dial fibrosis at d17 and d20. Both DO11.10+ and TCR-M Teff 
infiltrated the inflamed myocardium (Supp. Fig. 4). Injection 
of DO11.10+ Teff protected the heart from post-inflammatory 
fibrosis at later stage (day 40), as indicated by Masons Tri-
chrome staining (Fig. 6a, b), reduced hydroxyproline content 
(Fig. 6c), expression of profibrotic genes (Suppl. Fig. 5) and 
the amount of αSMA-positive and periostin-postive myofi-
broblasts (Fig. 6a, b). Instead, injection of TCR-M Teff or 
DO11.10+ Tn did not affect post-inflammatory fibrosis 
(Suppl. Fig. 6). Next, we addressed whether DO11.10+ Teff 
cells can affect cardiac function. As expected, echocardiog-
raphy analysis showed significantly compromised cardiac 
function in α-MyHC/CFA-immunized mice at day 40 with 
ejection fraction reduced from 58% before immunisation 
to 40% at d40 and fractional shortening from 29% before 
immunisation to 18% at d40. Treatment with DO11.10+ 
Teff cells prevented development of cardiac dysfunction in 
most animals (Fig. 6d and Suppl. Fig. 7). This better cardiac 
functions in mice receiving DO11.10+ Teff cells were paral-
leled by a lower heart weights comparing with α-MyHC/
CFA-immunized mice treated with PBS (Fig. 6e). All these 
data suggest that heart non-specific Teff cells can prevent 
development of DCM phenotype in the EAM model. 
Bystander activation of Teff suppress myofibroblast 
phenotype of mouse and human cardiac fibroblasts
The transcriptomic analysis showed that in contrast to heart-
specific CD45.1+  CD4+ T cells, unstimulated DO11.10+ 
Teff expressed low levels of extracellular molecules. In 
stimulatory condition (+α-MyHC), however, a set of 56 
genes encoding extracellular factors became specifically 
upregulated in heart non-specific DO11.10+ Teff, but not in 
α-MyHC-reactive CD45.1+ Teff (Fig. 4d). This suggested 
that antigen-independent stimulation of Teff might trigger 
production of certain antifibrotic factors. To address this 
option, we co-cultured DO11.10+ Teff with mouse cardiac 
fibroblasts in the presence or absence of IL-2, IL-7, IL-15 
and IL-21 (further called γc-cytokines). Analysis of profi-
brotic markers in cardiac fibroblasts showed that DO11.10+ 
Teff stimulated with γc-cytokines effectively suppressed 
expression of profibrotic genes Acta2, Col1a1 and Fn1 and 
reduced formation of αSMA fibers (Supp. Fig. 8).
Next, we addressed, whether or not, human Teff can 
affect the myofibroblast phenotype of human cardiac fibro-
blasts. A panel of phenotypic markers (CD45RO, CD45RA, 
CCR7, CD27) allows identification of  CD4+ T cell sub-
sets in humans (Supp. Fig.  9A). Using these markers, we 
sorted Tn  (CD45RO−CD45RA+CCR7+CD27+) and Teff 
 (CD45RO+CD45RA−CCR7−CD27−) from human periph-
eral blood and analyzed their proliferation in vitro. In contrast 
to Tn cells, human Teff showed some proliferation in response 
to γc-cytokine stimulation (Supp. Fig. 9B). In co-cultures with 
human cardiac fibroblasts, only Teff stimulated with γc-cytokines 
down-regulated expression of profibrotic genes ACTA2, COL1A1, 
and FN1 in fibroblasts (Fig. 7a). Furthermore, in co-cultures 
with Teff, cardiac fibroblasts showed less αSMA-positive fibers 
(Fig. 7b). The reduced αSMA and collagen-I protein content was 
confirmed by intracellular flow cytometry analysis (Fig. 7c). Since 
αSMA is implicated in the contractile function of fibroblasts, we 
observed impaired contraction of cardiac fibroblasts upon pre-
treatment with γc-cytokine-stimulated Teff (Fig. 7d). Suppres-
sion of myofibroblast signature in cardiac fibroblasts by Teff was, 
however, not associated with changes in proliferation or apoptosis 
(Supp. Fig. 10). Our data suggested that the antifibrotic effect of 
Teff required stimulation with γc-cytokines.
Discussion
Observations from animal models have pointed to a criti-
cal role of  CD4+ T cells and heart-specific autoimmunity 
in the development of myocarditis and cardiac fibrosis, 
Fig. 2  Cells with Teff signature effectively infiltrate cardiac tis-
sue. Indicated Teff (3–5 × 106) were adoptively transferred into sub-
lethally irradiated BALB/c recipients. Top panel a shows representa-
tive heart histology of the respective recipient 10 days after adoptive 
transfer. Bottom panel a shows immunohistochemistry for CD45.1 
and CD90.1 in hearts of indicated recipients. Scale bars = 100  μm. 
Panel b shows analysis of donor  CD4+CD45.1+ cells in blood (top) 
and heart (bottom) 10  days after adoptive transfer of CD45.1+ Teff. 
Analysis of donor CD45.1+ and DO11.10+ Teff in indicated organs 
10  days after adoptive transfer is shown in panel  c and quantifica-
tion of total heart-inflammatory  CD3+CD4+ DO11.10+ T cells is 
presented in  panel d. Arrows show gating strategies and numbers 
indicate percentage of cells in the adjacent gate. Data are represent-
ative of six mice, p value calculated with unpaired Student’s t-test. 
CD45.1+ Teff—CD4+ cells from α-MyHC-stimulated (72  h) spleno-
cytes/iLN cells of α-MyHC/CFA immunized CD45.1-tg mice (EAM 
d17); TCR-M Teff—CD4+ cells from α-MyHC-stimulated (72 h) sple-
nocytes of TCR-M-tg (CD90.1+) mice; DO11.10+ Teff—CD4+ cells 
from OVA-stimulated (72 h) splenocytes of DO11.10-tg mice
◂
 Basic Research in Cardiology (2020) 115:6
1 3
6 Page 8 of 15
however, surprisingly little experimental data addressed 
migration and expansion of autoreactive  CD4+ T cells in 
the EAM model. In α-MyHC/CFA immunized mice, essen-
tially only α-MyHC-reactive T cells could be activated with 
their antigen and turn into Teff phenotype. Our mouse data 
confirmed that α-MyHC-reactive Teff cells efficiently expand 
and accumulate in the inflamed cardiac tissue. Furthermore, 
we demonstrated Teff phenotype of heart infiltrating  CD4+ 
T cells also in human myocarditis. Animals housed under 
high hygiene standards lack, however, other antigen-acti-
vated Teff cells, which are commonly present in humans due 
to exposure to various infectious agents. To address migra-
tory properties of heart non-specific Teff, we used a T cell 
adoptive transfer model of DO11.10+  CD4+ T cells activated 
in vitro with OVA antigen and found that Teff cardiotropism 
was not restricted to heart-specific  CD4+ T cells. It seems 
that expression of specific homing molecules, rather than 
antigen-specificity primary controls migration of  CD4+ 
T cells into the cardiac tissue. In fact, such cardiotropic 
signature has been recently suggested [23]. In our model, 
we observed more efficient accumulation of heart-specific 
 CD4+ T cells during the early phase of inflammation, while 
heart non-specific  CD4+ T cells were more prevalent at later 
phases. This differential kinetics could be the result of dif-
ferential cell expansion/survival in the periphery and/or dif-
ferential expression of homing molecules by these two types 
of  CD4+ T cells.
Antigen-specific responses of α-MyHC-reactive  CD4+ 
T cells are crucial for myocarditis induction. Our results 
pointed to Th1/Th17 skewed antigen-dependent response 
of heart-specific Teff. On the one hand, Th1 cytokines are 
considered to be involved in the myocarditis induction at 
a very early stage [37]. Th17 polarized responses, on the 
other hand, have been associated with worsened myocarditis 
Fig. 3  Differential kinetic of 
antigen-dependent and antigen-
independent expansion of Teff 
during myocarditis. CD45.1+ 
Teff (4 × 106), TCR-M Teff 
(4.5 × 106) and DO11.10+ Teff 
(4.5 × 106) cells were co-deliv-
ered into sub-lethally irradiated 
BALB/c recipients. Panel a 
shows analysis of donor  CD4+ 
T cell frequency in indicated 
organs 4 days after adoptive 
transfer. Arrows show gating 
strategies and numbers indicate 
percentage of cells in the adja-
cent gate. Data are representa-
tive of four mice per time point. 
Panel b presents frequencies 
of indicated donor Teff among 
heart-infiltrating  CD4+ T cells 
at days 4 and 10 after adop-
tive transfer. Donor CD45.1+, 
TCR-M and DO11.10+ Teff were 
generated as described in Fig. 2
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outcome due to increased cardiac fibrosis and heart failure 
in both, EAM and human patients [2, 29, 31]. These data 
might suggest that myocardial fibrosis and DCM phenotype 
after α-MyHC/CFA immunization is a direct consequence 
of the Th1/Th17 polarisation of α-MyHC-reactive  CD4+ T 
cells. Furthermore, adoptive transfer experiments demon-
strated that heart-specific  CD4+ T cell mediated myocar-
ditis induction paralleled a strong bystander activation of 
heart non-specific  CD4+ T cells. Such antigen-independent 
expansion of activated Teff has been described in the con-
text of viral infections [13], in breast cancer [17] and after 
vaccination [10]. Insights from other disease models point 
to various innate stimuli [18, 32] and γc-cytokines [12, 
33] as potential mediators. We assume that in myocardi-
tis, mainly γc-cytokines produced by heart-specific  CD4+ 
Fig. 4  Transcriptomic analysis 
of heart-specific and heart 
non-specific Teff cells. CD45.1+ 
Teff (3 × 106) and DO11.10+ Teff 
(3 × 106) cells were co-delivered 
into sub-lethally irradiated 
BALB/c recipients. 10 days 
later, the whole splenocytes 
were isolated, stimulated with 
α-MyHC (or kept unstimu-
lated for controls) for 24 h 
and CD45.1+ and DO11.10+ 
 CD4+ cells were sorted for the 
whole transcriptome sequenc-
ing (RNAseq). Panel a illus-
trates the experimental setup. 
The number and the overlap 
of all differentially expressed 
genes (p < 0.05, log2ratio > 0.5 
or < −0.5) in response to 
α-MyHC in CD45.1+ Teff and 
in DO11.10+ Teff is shown in 
panel b. Panel c shows heatmap 
of genes of the cytokine activity 
GO:0005125 category up-
regulated (p < 0.05, log2ra-
tio > 0.75) in CD45.1+ Teff and/
or DO11.10+ Teff in response 
to α-MyHC treatment. Panel d 
shows heatmap of genes of the 
extracellular space GO:0005615 
category differentially expressed 
(p < 0.05, log2ratio > 0.75 
or < − 0.75) between CD45.1+ 
Teff and DO11.10+ Teff under 
stimulatory (+α-MyHC) condi-
tion. Cells obtained from 3 
independent mice were used for 
RNAseq. Donor CD45.1+ and 
DO11.10+ Teff were generated 
as described in Fig. 2
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T cells promote the antigen-independent response of heart 
non-specific  CD4+ T cells.
In our model heart non-specific Teff effectively competed 
with heart-specific Teff and eventually partially replaced 
them in the inflamed myocardium at later stages of disease. 
Our data showed that heart non-specific Teff produced a dis-
tinct set of cytokines compared to heart-specific Teff. This is 
not surprising, considering that heart-specific Teff responded 
to antigen (α-MyHC), while heart non-specific Teff showed 
antigen-independent response only. Interestingly, heart 
non-specific Teff expressed high levels of pro-inflammatory 
cytokines, such as Tnf, Lta or Mif. This result could explain 
why heart non-specific Teff did not affect the severity of the 
acute cardiac inflammatory response.
In contrast, adoptive transfer of heart non-specific Teff 
successfully prevented development of post-inflammatory 
fibrosis in the EAM model. We found that bystander acti-
vation of the heart non-specific Teff induced production of 
surprisingly high number of extracellular molecules. Some 
of these factors might be antifibrotic and thus actively inhibit 
fibrotic processes. Sfrp2 represents an example of such anti-
fibrotic agent, which was specifically expressed by activated 
heart non-specific Teff. We have recently demonstrated that 
systemic administration of sFRP2 during acute phase of 
myocarditis prevented development of fibrotic changes in 
the EAM model by blocking profibrotic Wnt signalling [5]. 
The in vitro data have also pointed to the secretion of antifi-
brotic factors by mouse and human Teff activated in antigen-
independent manner. Furthermore, heart non-specific Teff 
by replacing heart-specific Teff could reduce cardiac levels 
of profibrotic cytokines, such as IL-17A, in the inflamed 
heart. We consider these two mechanisms being responsible 
for antifibrotic effect of the heart non-specific Teff (Supp. 
Fig. 11). Noteworthy, the analysis of cytokine and extra-
cellular factors production by heart-specific and heart non-
specific Teff was performed on restimulated splenic cells 
only. Lack of data obtained from the heart-infiltrating Teff 
is a major limitation of this study. We did not perform such 
analysis due to technical difficulties.
Cardiac fibrosis is a key driver of DCM [6]. Accord-
ingly, in the EAM model, development of cardiac fibrosis 
was associated with impaired cardiac function and increased 
heart size [4]. Our data confirmed that function of fibrotic 
heart are significantly compromised in the α-MyHC/CFA 
EAM model (ejection fraction reduced from 58% before 
immunisation to 40% at d40). It is, therefore, not surprising 
Fig. 5  Heart non-specific Teff do 
not affect myocarditis severity. 
Myocarditis-inducing CD45.1+ 
Teff (4–6 × 106) were injected 
with or without DO11.10+ Teff 
(4–6 × 106) into sub-lethally 
irradiated BALB/c recipients. 
Representative histology (top) 
and immunohistochemistry 
for CD45 (middle) and CD3 
(bottom) in hearts of indicated 
recipients 10 days after adoptive 
transfer are shown in panel a. 
Scale bar = 100 μm. Myocarditis 
severity scores and quantifica-
tion of heart-infiltrating  CD3+ 
and  CD45+ cells are presented 
in panel b. p values calculated 
with unpaired Student’s t test. 
Donor CD45.1+ and DO11.10+ 
Teff were generated as described 
in Fig. 2
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that antifibrotic effect of heart non-specific Teff protected 
cardiac function and development of DCM phenotype. It 
should be noted that interplay between cardiac inflammation 
and fibrosis is of high relevance, not only in myocarditis, 
but also in other heart diseases [1]. These results further 
stress the importance of antifibrotic therapies for the posi-
tive outcome of myocarditis. A number of antifibrotic agents 
successfully prevented development of DCM phenotype in 
animal models [4, 5, 20, 25].
In contrast to the EAM model, heart-specific T cells are 
usually not the primary inducers of myocarditis in humans 
[7, 22]. Instead, viruses and parasites represent the most 
common triggers of lymphocytic infiltration in the myo-
cardium and heart-specific autoimmunity is predominantly 
associated with the disease progression [3, 8]. By shedding 
light on the importance of antigen-independent responses, 
our data provide a link between insights from animal mod-
els and observations in humans. Accordingly, our findings 
can potentially explain the difficulties in identifying heart-
specific  CD4+ T cells in human myocarditis. We suggest 
that inflammation-driven, antigen-independent migration 
and proliferation of Teff could account for extensive cardiac 
Fig. 6  Heart non-specific Teff 
prevents postinflammatory 
fibrosis and cardiac dysfunc-
tion. α-MyHC/CFA immunized 
BALB/c recipients received 
control solution (PBS) or 
DO11.10+ Teff (4–5 × 106) at 
days 17 and 20 of EAM and 
were analyzed for fibrotic 
and functional changes at day 
40. Panel a shows representative 
Masson’s Trichrome staining 
and immunohistochemistry 
stainings for periostin, vimentin 
and αSMA in heart sections. 
Scale bar = 200 μm. Quantifica-
tions of the fibrotic and immu-
nopositive areas are shown in 
panel b. p values calculated 
with the Mann–Whitney test. 
Panel c shows hydroxyproline 
content at day 40. Echocardi-
ography measurements were 
performed in mice before 
immunization (d0) and at d40 of 
EAM. Panel d shows difference 
for d40 and d0 (Δ = d40–d0) for 
selected parameters. EF ejection 
fraction, FS fractional shorten-
ing, CO cardiac output. p values 
calculated with the Student’s 
t test. All echocardiographic 
parameters at d0 and d40 are 
available in the Suppl. Table 2. 
Analysis of heart weights at d40 
is shown in panel e. HW/TL heart 
weight to tibial length. p values 
calculated with the Student’s t 
test. Donor DO11.10+ Teff were 
generated as described in Fig. 2
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accumulation of heart non-specific  CD4+ T cells. So far, 
there are no concrete data on the numbers of heart-reac-
tive  CD4+ T cells in human myocarditis, but consider-
ing that heart-specific  CD4+ T cells are rather infrequent 
in humans, we hypothesize that a significant proportion 
of heart-infiltrating  CD4+ T cells in myocarditis patients 
do not react against cardiac antigens. From this point of 
view, and given the antifibrotic and cardioprotective prop-
erties of heart non-specific Teff, significant infiltrations 
with  CD4+ T lymphocytes could even indicate favourable 
outcome in myocarditis. Indeed, most patients with lym-
phocytic myocarditis recover, while only some develop 
Fig. 7  Human Teff stimulated with γc-cytokines suppress myofibro-
blast signature of human cardiac fibroblasts. Human cardiac fibro-
blasts were co-cultured with sorted human Tn and Teff in the presence 
of IL-2, IL-7, IL-5 and IL-21 (γc-cytokines) for 7  days (human Tn 
and Teff were isolated as shown in Supp. Fig. 7). Panel a shows gene 
expression levels (normalized to GAPDH) in cardiac fibroblasts at 
day 7 at indicated conditions. Data are representative of three inde-
pendent experiments, p values calculated with one-way ANOVA, 
* p < 0.05 the Dunnett post hoc test compared to fibroblasts with 
γc-cytokines. Panel  b shows representative immunofluorescence 
for αSMA (green) and F-actin (phalloidin staining, red) and quanti-
fication of αSMA-positive cardiac fibroblasts cultured for 7  days in 
presence of γc-cytokines with or without human Teff. Data are repre-
sentative of three independent experiments, p value calculated with 
unpaired Student’s t-test. Scale bar = 50  μm. Panel c shows relative 
intracellular levels of αSMA and collagen I in cardiac fibroblasts in 
presence of γc-cytokines and Teff measured with flow cytometry. Data 
are shown as fold change from three independent experiments, p val-
ues calculated with unpaired Student’s t-test. Panel d shows contrac-
tion of cardiac fibroblasts in 3D collagen matrix after 5 days. Cardiac 
fibroblasts were pretreated with γc-cytokine-stimulated Tn or Teff for 
7  days. Data are representative of two independent experiments, p 
values calculated with one-way ANOVA, * p < 0.05 the Dunnett post 
hoc test compared to fibroblasts with γc-cytokines. ACTA2 alpha 
smooth muscle actin, COL1A1 collagen I, FN1 fibronectin, VIM 
vimentin
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DCM phenotype [11, 28]. The observation that chronic 
inflammation and long-term antigen activation alters Teff 
responses [16] supports our idea that a bystander activa-
tion of  CD4+ T cell protects myocarditis patients from 
progression to heart failure.
So far, investigations addressing the role of  CD4+ T 
cells in myocarditis focused on heart-specific autoimmun-
ity. Our data underline potential importance of antigen-
independent  CD4+ T cell responses in the progression 
from myocarditis to DCM and attribute them a cardiopro-
tective role. Individual differences in the capability of the 
immune system to express such functions could explain 
variable clinical outcomes of lymphocytic myocarditis. 
The relevance of our findings has to be validated in human 
patients, since EAM model only partially mimics the com-
plexity of naturally occurring myocarditis. At the same 
time, further research is needed to elucidate molecular 
mechanisms and to enable translation of these findings 
into appropriate therapeutic approaches.
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